These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 21502425)

  • 41. Cytogenetic evolution in myeloproliferative neoplasms with different molecular abnormalities.
    Kim SY; Koo M; Park Y; Kim H; Choi Q; Song IC; Jo DY; Kim J; Kwon GC; Koo SH
    Blood Cells Mol Dis; 2019 Jul; 77():120-128. PubMed ID: 31059941
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow.
    Ingram W; Lea NC; Cervera J; Germing U; Fenaux P; Cassinat B; Kiladjian JJ; Varkonyi J; Antunovic P; Westwood NB; Arno MJ; Mohamedali A; Gaken J; Kontou T; Czepulkowski BH; Twine NA; Tamaska J; Csomer J; Benedek S; Gattermann N; Zipperer E; Giagounidis A; Garcia-Casado Z; Sanz G; Mufti GJ
    Leukemia; 2006 Jul; 20(7):1319-21. PubMed ID: 16617322
    [No Abstract]   [Full Text] [Related]  

  • 43. Reply to Kremer M et al., the JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis.
    Ohyashiki K; Ohyashiki JH
    Leukemia; 2006 Jul; 20(7):1297-8. PubMed ID: 16617315
    [No Abstract]   [Full Text] [Related]  

  • 44. 3q26.2/EVI1 rearrangement is associated with poor prognosis in classical Philadelphia chromosome-negative myeloproliferative neoplasms.
    Hu Z; Medeiros LJ; Wang W; Chen Z; Tang G; Hodjat P; Yang S; Fang L; Li Y; Verstovsek S; Hu S
    Mod Pathol; 2017 Jul; 30(7):940-951. PubMed ID: 28338652
    [TBL] [Abstract][Full Text] [Related]  

  • 45. JAK2 exon 12 mutation in myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Not an exclusive mutation to polycythaemia vera.
    Inano T; Araki M; Morishita S; Imai M; Yasuda H; Nitta H; Ito M; Edahiro Y; Ochiai T; Misawa K; Fukuda Y; Ohsaka A; Komatsu N
    Br J Haematol; 2019 Oct; 187(1):e27-e31. PubMed ID: 31418453
    [No Abstract]   [Full Text] [Related]  

  • 46. Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript.
    Duployez N; Nibourel O; Ducourneau B; Grardel N; Boyer T; Bories C; Darre S; Coiteux V; Berthon C; Preudhomme C; Roche-Lestienne C
    Eur J Haematol; 2016 Oct; 97(4):399-402. PubMed ID: 26935241
    [TBL] [Abstract][Full Text] [Related]  

  • 47. JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases.
    Schnittger S; Bacher U; Kern W; Haferlach T; Haferlach C
    Leukemia; 2007 Aug; 21(8):1843-5. PubMed ID: 17443220
    [No Abstract]   [Full Text] [Related]  

  • 48. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course.
    Tam CS; Abruzzo LV; Lin KI; Cortes J; Lynn A; Keating MJ; Thomas DA; Pierce S; Kantarjian H; Verstovsek S
    Blood; 2009 Apr; 113(18):4171-8. PubMed ID: 19131547
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Concurrent
    Ye MT; Wang Y; Wang SA; Pemmaraju N; Daver N; Verstovsek S; Zhang Y; Zuo Z; Medeiros LJ; You MJ
    Leuk Lymphoma; 2020 Apr; 61(4):963-966. PubMed ID: 31750750
    [No Abstract]   [Full Text] [Related]  

  • 50. Myelodysplastic/myeloproliferative disease with erythropoietic hyperplasia (erythroid preleukemia) and the unique translocation (8;9)(p23;p24): first description of a case.
    Heiss S; Erdel M; Gunsilius E; Nachbaur D; Tzankov A
    Hum Pathol; 2005 Oct; 36(10):1148-51. PubMed ID: 16226118
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations.
    Vannucchi AM; Guglielmelli P
    Haematologica; 2008 Jul; 93(7):972-6. PubMed ID: 18591622
    [No Abstract]   [Full Text] [Related]  

  • 52. Amino acid residue E543 in JAK2 C618R is a potential therapeutic target for myeloproliferative disorders caused by JAK2 C618R mutation.
    Wu QY; Li F; Guo HY; Cao J; Chen C; Chen W; Zhao K; Zeng LY; Han ZX; Li ZY; Wang XY; Xu KL
    Arch Biochem Biophys; 2012 Dec; 528(1):57-66. PubMed ID: 22960131
    [TBL] [Abstract][Full Text] [Related]  

  • 53. JAK2: implications for diagnosis and classification of myeloproliferative disorders.
    Campbell P
    Lijec Vjesn; 2007 May; 129 Suppl 3():30-2. PubMed ID: 18959057
    [No Abstract]   [Full Text] [Related]  

  • 54. Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology.
    Gong JZ; Cook JR; Greiner TC; Hedvat C; Hill CE; Lim MS; Longtine JA; Sabath D; Wang YL;
    J Mol Diagn; 2013 Nov; 15(6):733-44. PubMed ID: 23978506
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.
    Jäger R; Gisslinger H; Passamonti F; Rumi E; Berg T; Gisslinger B; Pietra D; Harutyunyan A; Klampfl T; Olcaydu D; Cazzola M; Kralovics R
    Leukemia; 2010 Jul; 24(7):1290-8. PubMed ID: 20508609
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Research progress on gene mutation of jak2].
    Liu L; Li W; Liu N; Pang L; Feng SX; Zhao LL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1629-32. PubMed ID: 20030962
    [TBL] [Abstract][Full Text] [Related]  

  • 57. JAK2 V617F mutation is associated with 5q- syndrome in Chinese.
    Wong KF; Wong WS; Siu LL; Lau TC; Chan NP
    Leuk Lymphoma; 2009 Aug; 50(8):1333-5. PubMed ID: 19562618
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pathogenetic role of JAK2 gene mutation in chronic myeloproliferative disorders].
    Shide K
    Rinsho Ketsueki; 2008 Jul; 49(7):429-36. PubMed ID: 18709972
    [No Abstract]   [Full Text] [Related]  

  • 59. Myeloid neoplasm with translocation t(2;11)(p21;q23-24), elevated microRNA 125b-1, and JAK2 exon 12 mutation.
    McCormick SR; Higgins RR; Grutkoski PS; Bousquet M; Quelen C; Bartholomaus LM; Brousset P
    Br J Haematol; 2015 Apr; 169(2):290-3. PubMed ID: 25316507
    [No Abstract]   [Full Text] [Related]  

  • 60. Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) translocation.
    Bousquet M; Brousset P
    Hum Pathol; 2006 Apr; 37(4):500; author reply 500-2. PubMed ID: 16564930
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.